| Date | Title | Description |
| 19.05.2026 | Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology | Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating ... |
| 03.04.2026 | Ambrosia Biosciences Fuels Next-Gen Oral Metabolic Drug Development | Ambrosia Biosciences secured a monumental $100 million Series B funding. This capital injection immediately accelerates their oral small molecule GLP-1 candidate into pivotal clinical trials. It also vigorously advances their broader pipeli... |
| 01.04.2026 | Ambrosia Biosciences: $100 Million Raised For Cardiometabolic Small Molecule Pipeline Advancement | Ambrosia Biosciences announced that it has raised $100 million in an oversubscribed Series B financing round to advance its pipeline of orally delivered small molecule therapies targeting cardiometabolic diseases.
The financing was co-led b... |
| 31.03.2026 | Ambrosia Biosciences Raises $100M in Series B Funding | Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $100M in Series B funding.
The round was led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, with participation from existing investors BVF Partn... |
| 17.12.2025 | Impulse Dynamics Secures $158M for Advanced Heart Failure Therapies | Impulse Dynamics secured over $158 million in crucial financing. This capital propels the expansion of next-generation heart failure therapies. The company aims to broaden access to its cardiac contractility modulation (CCM) therapy. This i... |
| 15.12.2025 | Impulse Dynamics: Over $158 Million Raised To Advance Next Generation Heart Failure Devices | Impulse Dynamics, a medical device company focused on therapies for heart failure, said it has raised more than $158 million in financing to expand commercialization and support development across its clinical and technology pipelines.
The ... |
| 11.12.2025 | Impulse Dynamics Closes $158M Financing Round | Impulse Dynamics, a Marlton, NJ-based medical device company, raised $158M in funding.
Backers included Sands Capital, Braidwell, Redmile, Perceptive, Alger, and industry executives.
The company intends to use the funds to accelerate commer... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 07.08.2025 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
Thu, Aug 07, 2025 07:00 CET Report this content
Lund, Sweden August 7, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in... |
| 17.07.2025 | One Biosciences raises €15M Series A to advance precision oncology platform | One Biosciences, a precision oncology biotech company pioneering clinical grade single-cell tumour profiling, today announced €15 million Series A financing, bringing the company’s funding to €20 million.
One Biosciences aims to help clinic... |
| 17.07.2025 | One Biosciences Raises €15M in Series A Funding | One Biosciences, a Paris, France-based precision oncology techbio company, raised €15M in Series A funding.
The round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Poly... |
| 25.06.2025 | Neuron23: Pioneering Precision Medicine with a $96.5 Million Boost | In the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici... |
| 25.06.2025 | Neuron23 Raises $96.5M in Series D Financing | Neuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding.
The round wa sled by heal... |
| 24.06.2025 | Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological Medicines | Neuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar... |
| 21.02.2025 | Clear Labs Secures $30 Million in Series D Financing to Accelerate Development and Adoption of Cutting-Edge Sequencing Solutions | Clear Labs, a provider of fully automated and next-generation sequencing (NGS) platforms for turnkey diagnostics, announced it secured $30 million in its Series D financing. The funding round was led by a strategic investor, along with part... |
| 19.02.2025 | Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis | Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New... |
| 13.02.2025 | Abcuro Raises $200M in Series C Financing | Abcuro, a Newton, MA-based clinical-stage biotechnology company, raised $200M in Series C funding.
The round was led by New Enterprise Associates (NEA) joined by Foresite Capital with participation from existing investors including RA Capit... |
| 16.01.2025 | Clear Labs: $30 Million (Series D) Secured For Advancing Development Of Sequencing Solutions | Clear Labs, a provider of fully automated and next-generation sequencing (NGS) platforms for turnkey diagnostics, announced it has raised $30 million in its Series D financing. This funding round was led by a strategic investor, along with ... |
| 14.01.2025 | Saluda Medical Secures $100 Million to Revolutionize Pain Management | In the world of medical innovation, funding is the lifeblood that fuels progress. Saluda Medical, a Minneapolis-based company, has just secured a hefty $100 million in financing. This investment is not just a number; it represents hope for ... |
| 13.01.2025 | Saluda Medical Raises $100M in Funding | Saluda Medical, a Minneapolis, MN-based commercial-stage medical device company, raised $100M in funding.
The round was led by Redmile Group, with participation from existing investors Wellington Management, TPG Life Sciences Innovation, Fi... |
| 13.01.2025 | Clear Labs Secures $30 Million in Series D Financing to Accelerate Development and Adoption of Cutting-Edge Sequencing Solutions | Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for the clinical and applied markets.
Leader in Next-Generation Sequencing Advances Innovation in Healthcare with Capital and Appointment of ... |
| 13.01.2025 | Saluda Medical: $100 Million Of Financing Closed | Saluda Medical – a commercial-stage medical device company focused on developing treatments for chronic neurological conditions utilizing a novel closed-loop and dose-control neuromodulation platform – announced the closing of a $100 millio... |
| 13.01.2025 | Clear Labs Raises $30M in Series D Financing | Clear Labs, a San Carlos, CA-based provider of next-generation sequencing (NGS) platforms for diagnostics, raised $30M in Series D funding.
The round was led by a strategic investor, along with participation from existing investors, includi... |
| 25.07.2024 | GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment**
** | ** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round.... |
| 19.07.2024 | GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series B | GRO Biosciences (GRObio), a biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of an oversubscribed $60.3 million Series B fin... |
| 19.06.2024 | ElevateBio: компания по производству генетических лекарств | Содержание
История компании
Технологии: объединение производства и некстген технологий терапевтического производства
Экосистема компании
BaseCamp
Партнеры
Отраслевые партнерства
Академические партнерства
Привлечение инвестиций История компа... |
| 27.05.2024 | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Mon, May 27, 2024 10:00 CET Report this content
Lund, Sweden May 27, 2024, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gi... |
| 09.09.2021 | Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures | -- Advancing novel targeted therapeutics using its LYTAC protein degradation technology --
-- Plans to use $105 million in recent capital, including $35 million upfront payment from strategic collaboration with Lilly, to progress internal p... |
| 09.09.2021 | Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures | - |
| 01.08.2018 | Redmile raises $218m for first biopharma fund | Redmile Group has raised more than $218m for its Biopharma Investments I vehicle. The San Francisco-based fund has rece |
| 23.10.2017 | ADC Therapeutics Announces Closing of $200 Million Private Financing | |
| 08.03.2017 | From real estate to healthcare: Trulia cofounder’s new health IT venture takes on Type 2 diabetes (Updated) | Two years after Zillow acquired online real estate company Trulia in a $2.5 billion deal, Trulia’s Cofounder and former president Sami Inkinen has moved into healthcare with the launch of telehealth startup, Virta Health. The digital health... |
| - | From real estate to healthcare: Trulia cofounder’s new health IT venture takes on Type 2 diabetes (Updated) | Virta Health physicians Caroline Roberts and Jeff Stanley
This post has been updated to include comments from a phone interview with Virta Health cofounder and CEO Sami Inkinen.
Two years after Zillow acquired online real estate company Tru... |
